leadf
logo-loader
viewEnzychem Lifesciences

Enzychem Lifesciences advancing its therapy derived from deer antlers

Enzychem Lifesciences Corp (KOSDAQ:183490) CEO Ki Young Sohn sat down with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. The South Korea and New Jersey-based biopharma company's lead compound is an immune resolution accelerator that is derived from deer antlers, with the potential to be used for a variety of indications.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

FTSE up as government keep cap on gas prices with energy market in focus

FTSE 100 jumped back near the 7,000 mark even though government borrowing was higher than expected in August. London’s leading index added 64 points to 6,968 in early trading.   The UK government has decided to keep the cap on how much energy suppliers can charge customers to protect the...

1 hour, 28 minutes ago

2 min read